Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.88 USD | -1.09% | +3.72% | -0.09% |
Apr. 30 | Tranche Update on Zynex, Inc.'s Equity Buyback Plan announced on February 29, 2024. | CI |
Apr. 30 | Tranche Update on Zynex, Inc.'s Equity Buyback Plan announced on November 1, 2023. | CI |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's profit outlook over the next few years is a strong asset.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-0.09% | 346M | C | ||
+12.15% | 227B | B | ||
+14.90% | 197B | B- | ||
+18.22% | 141B | B- | ||
+29.15% | 110B | A- | ||
+1.56% | 64.15B | A- | ||
+16.92% | 53.72B | B+ | ||
+6.33% | 51.75B | B+ | ||
+10.93% | 45.2B | A | ||
+5.87% | 37.37B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ZYXI Stock
- Ratings Zynex, Inc.